Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03802461
Other study ID # 18-5177
Secondary ID
Status Suspended
Phase Phase 2/Phase 3
First received
Last updated
Start date March 22, 2019
Est. completion date March 20, 2024

Study information

Verified date November 2022
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Carbapenemase-producing Enterobacteriaceae (CPE) are bacteria carried in the gastrointestinal tract that are resistant to carbapenems, antibiotics of last resort. CPE infections result in death in 25-50% of cases. Fecal microbiota transplantation (FMT) is the transfer of stool from a healthy donor to a recipient to alter the composition of gut microbes. Early studies support its use for eliminating CPE carriage but definitive studies are lacking. The investigators propose a feasibility pilot for a multicenter, non-blinded randomized trial comparing the effectiveness of FMT with no intervention (standard of care) in eliminating intestinal carriage of CPE. Forty patients with CPE will be randomly assigned to receive FMT by enema or no intervention. Feasibility will be demonstrated by the ability to recruit and retain 40 patients over 12 months, and to provide FMT made at a central site to at least one off-site hospital. The primary clinical endpoint for the full trial is CPE intestinal carriage 3 months after the intervention. Secondary endpoints include: CPE carriage at 1, 6 and 12 months; time to decolonization of CPE; safety; CPE infections over 12 months; and, intestinal carriage of other antibiotic-resistant organisms. Data on the clinical outcomes will be collected but not analyzed in this feasibility study.


Description:

This is a multisite, open-label randomized controlled internal pilot trial designed to assess the feasibility of a larger trial aimed at determining the effectiveness of fecal microbiota transplantation (FMT) by enema in short and long term intestinal decolonization of carbapenemase-producing Enterobacteriaceae (CPE). Forty (40) asymptomatic adult patients intestinally colonized with CPE will be allocated in a 1:1 ratio to receive a bowel preparation followed by FMT by enema route, versus standard of care (no intervention). FMT will be provided by the University of Toronto Microbiota Therapeutics Outcomes Program (MTOP), using standardized operating procedures for recruiting and screening FMT donors, manufacturing FMT and administering FMT by enema. The feasibility outcomes are: successful randomization of 40 patients within 12 months, retention of >90% (36/40) of patients up to 6 months, and provision of FMT at a non-primary study site in at least one patient. Data on the clinical and exploratory outcomes will be collected but not analyzed in this pilot study. The primary clinical outcome is incidence of intestinal decolonization of CPE at 3 months. Secondary clinical outcomes include: time to decolonization of CPE; incidence of CPE clinical infections up to 12 months post-intervention; incidence of intestinal decolonization of CPE and other antibiotic-resistant organisms (extended spectrum beta-lactamase Enterobacteriaceae - ESBLs and vancomycin-resistant Enterococci - VRE) at 1, 3, 6 and 12 months post-intervention; and, safety profile. As an exploratory outcome, changes in fecal microbiome composition will be examined before and after intervention. This study leverages existing support, research infrastructures and expertise - including the Toronto Invasive Bacterial Diseases Network (TIBDN), Toronto Antimicrobial Resistance Research Network (TARRN), and the University of Toronto Microbiota Therapeutics Outcomes Program (MTOP) - to optimize feasibility regarding patient recruitment and FMT administration.


Recruitment information / eligibility

Status Suspended
Enrollment 40
Est. completion date March 20, 2024
Est. primary completion date December 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years 2. = 1 rectal swab, groin, stool, or urine specimen positive for a CPE within the past 1 month. • Presence of CPE will be confirmed at baseline through collection of pooled groin/rectal swab and urine specimen. 3. Women of childbearing age must be using at least one reliable form of birth control. 4. Must be able to provide informed consent. Exclusion Criteria: 1. Active infection with CPE at the time of assessment. 2. Pregnancy, planned pregnancy or breastfeeding. 3. Current admission to intensive care unit. 4. Significantly immunocompromised patients . - neutropenia (ANC < 1) - ongoing use of systemic corticosteroids > 30 mg/day - ongoing use of biologic therapy - undergoing chemotherapy, received chemotherapy = 30 days from baseline visit, or expected to undergo chemotherapy in the upcoming 12 months - active hematologic malignancy - solid organ transplant recipient - hematopoetic stem cell transplant recipient - HIV positive patients with cluster differentiation 4 (CD4) cell count < 350 5. Patients with ascites or receiving peritoneal dialysis. 6. History of inflammatory bowel disease (Crohn's or Ulcerative colitis). 7. Chronic diarrhea or active colitis for any reason. 8. Ileus or active gastrointestinal motility disorder at baseline. 9. History of total colectomy. 10. Severe, irreversible bleeding disorder. 11. History of anaphylactic or anaphylactoid allergic reaction to any foods. 12. Anticipated life expectancy less than 6 months. 13. Unable to tolerate enema. 14. Participant is not a Canadian citizen or permanent resident, and not expected to remain in Toronto region for 12 months. 15. Any reason in the view of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Fecal Microbiota Transplantation (FMT)
Feces from healthy donor

Locations

Country Name City State
Canada William Osler Health System Brampton Ontario
Canada Joseph Brant Hospital Burlington Ontario
Canada Lakeridge Health Oshawa Ontario
Canada MacKenzie Health Richmond Hill Ontario
Canada The Scarborough Hospital Scarborough Ontario
Canada Michael Garron Hospital Toronto Ontario
Canada North York General Hospital Toronto Ontario
Canada Public Health Ontario Laboratories Toronto Ontario
Canada Sinai Health System Toronto Ontario
Canada St Michael's Hospital Toronto Ontario
Canada St. Joseph Health Centre Toronto Ontario
Canada Sunnybrook Health Sciences Centre Toronto Ontario
Canada University Health Network Toronto Ontario

Sponsors (5)

Lead Sponsor Collaborator
Susy Hota Public Health Ontario Laboratories, Ontario, Canada, Sinai Health System, Ontario, Canada, The Toronto Invasive Bacterial Diseases Network, Ontario, Canada, University of Toronto, Ontario, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in composition and diversity of fecal bacterial phyla (as measured by 16s ribosomal ribonucleic acid sequencing) in both intervention groups As above 12 months
Primary Incidence of intestinal colonization of patients with CPE 3 months after intervention. Incidence of CPE colonization in FMT arm vs control arm at 3 months 3 months
Primary Randomization rate in study Completion of randomization of 40 study participants during the study period will be used to indicate feasibility of the study. 12 months
Primary Proportion of patients retained in study for up to 6 months A retention of 90% of patients up to 6 months in the study will be used to indicate feasibility. 6 months
Secondary Incidence of CPE decolonization in FMT-treatment and non-treatment groups at 1, 6 and 12 months. As above 1, 6, and 12 months
Secondary Time to CPE decolonization in FMT-treatment and non-treatment groups. As above 1, 3, 6, and 12 months
Secondary Incidence of CPE clinical infection in FMT treatment and non-treatment groups over 12 months. As above 1, 3, 6, and 12 months
Secondary Incidence of extended spectrum beta-lactamase organisms (ESBL) and vancomycin-resistant Enterococci (VRE) intestinal colonization at 0, 1, 3, 6 and 12 months in FMT treatment and non-treatment groups. Changes in colonization status of other antimicrobial resistant organisms over the study period 1, 3, 6, and 12 months
Secondary Incidence of solicited and unsolicited adverse and serious adverse events in both groups Participants will be asked to report adverse and serious adverse events will be throughout the study period and will be asked specifically about adverse events during study visits 3 months
Secondary Number of patients with all-cause mortality at 30 days post-randomization As above 1 month
See also
  Status Clinical Trial Phase
Completed NCT04529421 - Assocation Between In-person Instruction and COVID-19 Risk
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Recruiting NCT00342589 - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Completed NCT03296423 - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly Phase 4
Withdrawn NCT04217252 - Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection N/A
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Withdrawn NCT02904434 - Gastrointestinal Implications of Voriconazole Exposure
Active, not recruiting NCT02768454 - Antimicrobials Stewardship by Pharmacist N/A
Completed NCT02219776 - Decreasing Infection In Arthroscopic Shoulder Surgery N/A
Completed NCT02210169 - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates N/A
Recruiting NCT02098226 - Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts N/A
Completed NCT01846832 - A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection Phase 3
Completed NCT01434797 - Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
Terminated NCT01441206 - Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants Phase 1
Completed NCT01159834 - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) N/A